TIDMNSCI
NetScientific PLC
02 August 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
ProAxsis strengthens respiratory diagnostic portfolio by
receiving CE Mark for third respiratory immunoassay
- ProteaseTag(R) Active Proteinase-3 Immunoassay aimed at
researchers studying COPD, cystic fibrosis, and bronchiectasis
London, UK - 02 August, 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces that its portfolio company
ProAxsis Limited ("ProAxsis") has successfully registered a CE Mark
for its novel ProteaseTag(R) Active Proteinase-3 Immunoassay, which
has been accompanied by an immediate first commercial sale of
c.GBP,5,000 to a large US-based biotechnology company. The
immunoassay has been developed in conjunction with the
biotechnology company as a result of an ongoing collaboration in
the respiratory field.
Proteinase 3 is a neutrophilic protease, which has been
associated with respiratory diseases such as Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis (CF), and bronchiectasis.
The immunoassay will be marketed to clinical researchers
investigating chronic respiratory conditions in both the commercial
sector and academia.
Commenting on the news, NetScientific's Chief Executive Officer
and ProAxsis' Chairman, Francois R. Martelet, said: "We are pleased
to see ProAxsis consolidate its position as a leader in respiratory
diagnostics, and encouraged to see the results of a successful
collaboration between ProAxsis and its US biotech partner. This
assay has significant potential for utilisation in respiratory
trials for COPD, cystic fibrosis, and bronchiectasis, both in the
pharmaceutical sector and in academia, and we look forward to
registering further sales."
The ProteaseTag(R) Active Proteinase-3 Immunoassay is the third
ProAxsis product to be successfully CE marked, after its Plasmin
and Neutrophil Elastase immunoassays. Development is underway for
further immunoassays, some in collaboration with its US-based
biotechnology partner.
ProAxsis also markets NEATstik(R), a rapid point-of-care test
for measuring active neutrophil elastase, which is also a
well-recognised biomarker of lung inflammation and infection in
chronic respiratory diseases, alongside the ProteaseTag(R) Active
Neutrophil Elastase Immunoassay. A range of other laboratory-based
immunoassays and point-of-care tests designed for routine
monitoring of chronic diseases are in development.
NetScientific holds 54% of ProAxsis on a fully diluted
basis.
The full text of the announcement from ProAxsis can be found
below.
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite, CFO
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Tel: +44 (0)20 3709 5700
Hodgson / netscientific@consilium-comms.com
Chris Welsh / Laura Thornton
Tel: 020 7220 1666
WH Ireland (NOMAD and Broker)
Chris Fielding / Jessica Cave
/ Chris Viggor
ProAxsis receives CE Mark for additional respiratory
immunoassay
Date: 02 August 2018
ProAxsis Limited (www.proaxsis.com), the Belfast-based company
focused on developing new assays for the measurement of active
protease biomarkers of disease, today announces that it has
successfully registered a CE Mark for its novel ProteaseTag(R)
Active Proteinase 3 Immunoassay. Furthermore, the company confirms
an immediate first commercial sale for this new immunoassay.
Proteinase 3 is a neutrophilic protease, which has been
associated with causing inflammation and destruction of the lung
matrix in respiratory diseases such as Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis (CF) and bronchiectasis.
The ProteaseTag(R) Active Proteinase 3 Immunoassay was developed by
ProAxsis in collaboration with a US-based biotechnology company as
part of an ongoing collaboration.
Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said:
"There is increasing interest in the development of new products
which inhibit neutrophilic proteases, such as Proteinase 3, as
therapeutics for inflammatory diseases. This has driven the need
for reliable methods for quantification of active Proteinase 3 in
clinical samples. We are delighted to have collaborated with our US
partners on this successful development programme and anticipate
that this new immunoassay will be of significant value to both
academic and pharmaceutical company researchers working in this
field."
Any queries concerning ProAxsis' immunoassay for measuring
active Proteinase 3, or any requests for support with measuring
other active protease biomarkers using the Company's proprietary
ProteaseTag(R) technology, can be directed to
info@proaxsis.com.
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About ProAxsis Limited:
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of disease.
Its first commercialised immunoassay measures neutrophil elastase,
a leading indicator of infection and inflammation in patients with
Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD)
and bronchiectasis, and an important drug target. The rapid and
easy-to-use tests being developed by ProAxsis incorporate patented
ProteaseTags(R); smart molecules which trap an active protease
within a complex biological sample and enable a visual readout of
its presence. ProteaseTags(R) provide a unique tool to identify and
quantify active protease biomarkers and will assist in the clinical
validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the
Group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZFLFBVVFEBBZ
(END) Dow Jones Newswires
August 02, 2018 02:03 ET (06:03 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024
